Super M, Levinsky R J, Turner M W
Department of Immunology, Institute of Child Health, London, England.
Clin Exp Immunol. 1990 Feb;79(2):144-50. doi: 10.1111/j.1365-2249.1990.tb05170.x.
When sera diluted to 5% in a buffer containing calcium and magnesium were incubated with mannan-coated ELISA plates, C4 fragments, properdin and factor B were bound to the plates as well as the expected opsonic C3 fragments, C3b and C3bi. The calcium-dependent lectin mannan-binding protein, which is structurally similar to C1q, was also shown to bind in this assay and analysis of sera from 179 healthy blood donors revealed that the binding levels of all these proteins were highly significantly correlated. Results obtained with a previously described C3b opsonic assay using zymosan also correlated with the mannan-binding levels. When the sera were diluted to 5% in the presence of Mg-EGTA there was no detectable binding of complement proteins to the mannan surface, confirming that no alternative pathway activation occurred at this serum concentration. When sera were diluted to 5% in a buffer containing EDTA in order to study immunoglobulin binding in the absence of complement activation, the levels of bound IgG1, IgG2, IgG3, IgA and IgM antibodies were found to be completely unrelated to the C3bi binding levels previously observed. The results suggest that in this experimental system using low concentrations of serum, mannan-binding protein initiates an antibody-independent mechanism of cleavage of the classical pathway component C4, which subsequently regulates the degree of cleavage of C3 and recruitment of alternative pathway proteins.
当在含有钙和镁的缓冲液中稀释至5%的血清与甘露聚糖包被的ELISA板孵育时,C4片段、备解素和B因子以及预期的调理素C3片段C3b和C3bi都与板结合。结构与C1q相似的钙依赖性凝集素甘露聚糖结合蛋白在该检测中也显示出结合,对179名健康献血者血清的分析表明,所有这些蛋白的结合水平高度显著相关。使用酵母聚糖的先前描述的C3b调理素检测获得的结果也与甘露聚糖结合水平相关。当血清在Mg-EGTA存在下稀释至5%时,未检测到补体蛋白与甘露聚糖表面的结合,证实在此血清浓度下未发生替代途径激活。当血清在含有EDTA的缓冲液中稀释至5%以研究在无补体激活情况下的免疫球蛋白结合时,发现结合的IgG1、IgG2、IgG3、IgA和IgM抗体水平与先前观察到的C3bi结合水平完全无关。结果表明,在这个使用低浓度血清的实验系统中,甘露聚糖结合蛋白启动了经典途径成分C4的抗体非依赖性裂解机制,随后调节C3的裂解程度和替代途径蛋白的募集。